PCSK9 and endothelial dysfunction: Therefore, this study aimed to investigate the potential of PCSK9 inhibitor therapy to alleviate inflammation and endothelial dysfunction in the early phase of AMI by measuring TNF-α levels and the L-arginine/ADMA ratio.